PubMed 19. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987–9.PubMedCrossRef 20. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer

Res 2004, 64:3731–6.PubMedCrossRef 21. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal IWP-2 research buy cancer. Nat Med 2004, 10:145–7.PubMedCrossRef 22. Willett CG, Duda DG, di Tomaso E, et al.: Efficacy, safety, and biomarkers of neoadjuvant

bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020–6.PubMedCrossRef 23. Crane CH, Ellis LM, Abbruzzese JL, et al.: Phase I trial evaluating the safety of bevacizumab click here with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006, 24:1145–51.PubMedCrossRef 24. Seiwert TY, Haraf DJ, Cohen EE, et al.: Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008, 26:1732–41.PubMedCrossRef AZD6738 concentration Competing interests Dr. Paul M. Harari received research funding from NCI/NIH and Genentech Inc (paid to the University of Wisconsin) as well as patents and royalties (paid to Dr. Harari and the Wisconsin Alumni Research Foundation). Other authors Adenosine triphosphate do not have conflict of interest. Authors’ contributions TH participated in the design of the study, carried out experiments, performed data analysis, and drafted the manuscript. SH

participated in the design of the study, assisted in xenograft experiments and data analysis, and edited the manuscript draft. EA participated in the design of the study, assisted in experiments, data analysis and manuscript draft. JCE performed statistical analysis, assisted in data analysis and manuscript draft. PMH participated in the design of the study, performed data analysis, and edited the manuscript draft. All authors read and approved the final manuscript.”
“Introduction Tumor cells homing to form bone metastases is common in non-small cell lung cancer (NSCLC), just like what is seen in breast, prostate and thyroid cancers. Some patients may experience bone metastasis many years after surgery of the primary tumor. The high morbidity and significantly increased risk of fractures associated with bone metastasis seriously affect patients’ quality of life. About 36% of all lung cancers and and 54.5% of stage II-IIIA NSCLC showed postoperative recurrence or metastasis [1]. Many lung cancer patients expect new and more sensitive markers to predict metastatic diseases.